Memantine in Patients With Chronic Glaucoma

This study has been completed.

Sponsored by:	Allergan
Information provided by:	Allergan
ClinicalTrials.gov Identifier:	NCT00168350

Purpose

Randomized double-masked clinical trial of memantine in patients with glaucoma

Condition	Intervention	Phase
Open-Angle Glaucoma	Drug: memantine	Phase III

Genetics Home Reference related topics: early-onset glaucoma

MedlinePlus related topics: Glaucoma

Drug Information available for: Memantine Memantine hydrochloride

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study

Further study details as provided by Allergan:

Primary Outcome Measures:

Progression of glaucoma

Enrollment:

1100

Eligibility

Ages Eligible for Study:	18 Years to 82 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

glaucoma damage on examination of visual field and optic disc
good visual acuity (with glasses if needed)

Contacts and Locations

No Contacts or Locations Provided

More Information

Study ID Numbers:	192944-005
Study First Received:	September 9, 2005
Last Updated:	December 18, 2007
ClinicalTrials.gov Identifier:	NCT00168350
Health Authority:	United States: Food and Drug Administration

Study placed in the following topic categories:

Excitatory Amino Acids
Dopamine
Glaucoma
Eye Diseases

Glaucoma, Open-Angle
Memantine
Hypertension
Ocular Hypertension

Additional relevant MeSH terms:

Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Anti-Dyskinesia Agents
Therapeutic Uses
Physiological Effects of Drugs
Antiparkinson Agents

Excitatory Amino Acid Agents
Dopamine Agents
Central Nervous System Agents
Pharmacologic Actions
Excitatory Amino Acid Antagonists

ClinicalTrials.gov processed this record on January 13, 2009